Alvogen is building a regional platform for growth across the APAC region, with commercial network in 11 countries. The company has manufacturing and R&D centres in Korea and Taiwan and hundreds of products on the market.
Since 2012, Alvogen has completed three strategic acquisitions in Korea and Taiwan and aim to build a top 5 regional player by 2017. In Korea, Alvogen operates under the name of Kunwha Pharmaceuticals and in Taiwan as Lotus Pharmaceuticals.
Alvogen’s Asia Pacific commercial hub currently encompasses a broad range of countries including Korea, Taiwan, Myanmar, Thailand, Vietnam, Philippines, Singapore, Malaysia, Hong Kong and China. Alvogen has manufacturing and R&D hubs in Korea and Taiwan through its subsidiaries: Lotus Pharmaceuticals (Taiwan) and Alvogen Korea.
Is the Executive Vice President of Asia Pacific. He joined Alvogen in December 2009, after nine years with the generic pharmaceuticals company Actavis Group in various roles – Sales Representative, Division Head in Central Marketing and Senior Manager in Global Business Development.
“In a short period of time, we have built a strong platform for growth in Asia. We have made significant investments in high quality manufacturing and the successful integration of Kunwha, Dream pharma and Lotus. Our strong regional management team will drive our business forward and leverage on our growing global pipeline and geographical reach.”
- (Petar Vazharov, EVP of Sales in Asia Pacific)